mTOR inhibitors gaining favor for breast cancer treatment
Emory Health Now (blog)
Ruth O'Regan, MD, director of the Translational Breast Cancer Research Program at Winship Cancer Institute, has led clinical studies of everolimus in breast cancer and has championed the strategy of combining mTOR inhibitors with current treatments for ...
Two drugs appear to delay cancer progression
Experimental breast-cancer drugs show promise
Big promise is seen in 2 new breast cancer drugs